Congenital Portosystemic Shunts in Children: Recognition, Evaluation, and Management

O. Bernard, MD, PhD1 S. Franchi-Abella, MD2 S. Branchereau, MD3 D. Pariente, MD2 F. Gauthier, MD3 E. Jacquemin, MD, PhD1

1 Hépatologie pédiatrique, Hôpital Bicêtre, AP-HP, Université Paris-Sud, Le Kremlin-Bicêtre, France
2 Radiologie pédiatrique, Hôpital Bicêtre, AP-HP, Université Paris-Sud, Le Kremlin-Bicêtre, France
3 Chirurgie pédiatrique, Hôpital Bicêtre, AP-HP, Université Paris-Sud, Le Kremlin-Bicêtre, France

Address for correspondence and reprint requests Emmanuel Jacquemin, MD, PhD, Hépatologie Pédiatrique, Hôpital Bicêtre, AP-HP, Université Paris-Sud, 78 rue du Général Leclerc, Le Kremlin Bicêtre, France 94275 (e-mail: emmanuel.jacquemin@bct.aphp.fr).


Abstract

Congenital portosystemic shunts are present in one in 30,000 children. Among the associated risks of severe complications are neonatal cholestasis, benign and malignant liver tumors, hepatopulmonary syndrome, portopulmonary hypertension, and encephalopathy. They can be detected on prenatal ultrasonograms, during the investigation of a positive galactosemia screening test in neonates or of a complication, or be found fortuitously on an abdominal ultrasound. Small intrahepatic shunts may resolve spontaneously within one year of age, but other shunts such as extrahepatic, persistent ductus venosus or persisting intrahepatic shunts, must be closed in one or two steps, by interventional radiology techniques or surgically. The plasticity of the intrahepatic portal system allows revascularization of the liver after shunt closure, even when no intrahepatic portal structures can be detected on imaging studies. This leaves little or no place for liver transplantation in the management of these children.

Keywords

► portosystemic shunts
► children
► liver tumors
► hepatopulmonary syndrome
► pulmonary hypertension

The development of the liver results from epithelial and mesenchymal interactions connected to a network of early embryonic and then fetal vessels, some of which later involute both inside and outside the liver1; the ductus venosus, the last vessel to involute, normally disappears after a few days in term neonates, and after a few weeks in premature babies.2 The lack of complete involution of one or several of these primordial vessels may give rise to abnormal vascular communications between any vein of the portal system and any vein of the inferior vena cava system; these communications may exist inside or outside the liver, may be single or multiple, and vary in size. They can cause partial or complete diversion of the portal blood to the systemic vessel and carry risks of complications. They differ from the acquired intra- and extrahepatic portosystemic shunts occurring as a consequence of portal hypertension. Over the past 30 years, there has been an exponential increase in the number of children with congenital portosystemic shunts (CPSSs) reported in the English language literature (►Fig. 1). The present review is based on the study of 265 such children aged 16 years or less at the time of the first symptoms or diagnosis: 250 children reported in the literature between 1979 and early 20123–140, and 15 who were investigated at the Bicêtre Hospital since our publication of 22 patients in 2010.118

Anatomy

It has been customary to classify CPSS into two categories, extrahepatic and intrahepatic, respectively. Extrahepatic shunts often called “Abernethy malformations” are further classified into types 1 and 2 depending on the patency (type 2) or apparent lack of patency of the portal trunk and intrahepatic portal system.21,28 The type 1 extrahepatic CPSS, sometimes called “congenital absence of the portal vein,” was thought to require liver transplantation for a cure,67,86,87,128 whereas type 2 extrahepatic CPSS was amenable to closure, surgically or by interventional radiology procedures.132 On the other hand, intrahepatic CPSSs are located inside the liver and were classified into four categories.141 Although useful to some extent, these classifications
are no longer fully valid for several reasons: (1) intra- and extrahepatic shunts carry the same risks of complications; (2) the intrahepatic classification was described mostly in adult patients with cirrhosis and may not be adapted to CPSSs in children; (3) the classifications do not take into account the persistence of the ductus venosus, a significant type of CPSS that cannot fit into an intra- or extrahepatic category; (4) there have been reports in which both extra- and intrahepatic shunts were present in the same child; and (5) as far as extrahepatic shunts are concerned, assessment of the patency of the portal trunk and of its intrahepatic branches may give different results depending on the imaging technique. Successful portal revascularization of the liver has been reported after closure of the shunt in children in whom no portal vein had been seen, either during surgical examination or on an angiogram during an occlusion test, thus clearly showing the plasticity of the intrahepatic portal system.

Consequently, the term “congenital absence of the portal vein” is misleading. Based on the results of imaging studies, we suggest that the PSSs be classified anatomically, taking the following into account: the part of the portal system where the shunt originates, including the afferent veins of the portal trunk (e.g., the splenic or superior mesenteric vein), the portal trunk itself, or intrahepatic branches; the systemic vein of termination of the shunt and the ductus venosus; the type of communication with the systemic vein (end-to-side versus side-to-side); and the number of communications (single vs multiple). The respective anatomic types of CPSS reported in the pediatric literature are indicated in Table 1.

**Liver Pathology**

The liver is usually small, and amounts to 45 to 65% of the estimated standard volume for age. In children with so-called congenital absence of the portal vein, direct examination of the extrahepatic portal system during surgery or of the explanted liver at transplantation or autopsy, either did not show any portal venous structure or remnants, or showed vestigial fibrous remnants of the portal trunk at the porta hepatis, and sometimes showed a patent portal bifurcation with a break after the emergence of the right and left portal branches; this does not preclude the presence and plasticity of the intrahepatic portal system: A detailed study of the liver of a child with a type 1 Abernethy malformation reports the presence of small caliber portal veins in the large portal tracts although no portal vein was found in the hilum; this explains why closure of the shunt may revascularize the intrahepatic portal system, possibly through a small portal cavernoma probably developed from the peribiliary plexus and without significant portal hypertension.

Liver histology, described in 62 children, was reported as normal in 16 children, as a fatty liver with no or little portal fibrosis in six children, and as a pattern reminiscent of hepatoporal sclerosis in 40: Minimal or moderate portal fibrosis, absent or hypoplastic portal vein branches in the portal tracts, large arterial branches with sometimes a thickened wall, portal and periportal proliferation of thin vascular, capillary, or lymphatic structures, and in one instance, slight ductular proliferation. Perisinusoidal fibrosis or early-stage nodular regeneration was sometimes present. This pattern is similar to the one described in rats and is probably the consequence of portal blood deprivation.

**Prevalence and Possible Mechanisms**

Two studies use the results of neonatal screening for galactosmia after a few days of feeding to estimate the prevalence of congenital portosystemic shunts: High concentrations of blood galactose, unexplained by an abnormal activity of the enzymes of galactose metabolism, can be found in neonates...
Table 1: Anatomy of Congenital Portosystemic Shunts Reported in 265 Children

<table>
<thead>
<tr>
<th>Vein of Origin</th>
<th>Vein of Termination</th>
<th>Children Reported</th>
<th>Patent Portal Vein*</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portal branches</td>
<td>Hepatic vein ± IVC</td>
<td>2</td>
<td>2</td>
<td>118</td>
</tr>
<tr>
<td>Right portal branch</td>
<td>Inferior vena cava</td>
<td>9</td>
<td>9</td>
<td>10, 12, 14, 28, 69, 103, 118, 138</td>
</tr>
<tr>
<td></td>
<td>Hepatic vein(s)</td>
<td>17</td>
<td>10/12</td>
<td>15, 19, 26, 68, 68, 80, 108, 118, 120, 126, 137B</td>
</tr>
<tr>
<td>Left portal branch</td>
<td>Inferior vena cava</td>
<td>3</td>
<td>3</td>
<td>77, 118</td>
</tr>
<tr>
<td></td>
<td>Hepatic vein(s)</td>
<td>15</td>
<td>15</td>
<td>32, 46, 74, 103, 118, 124, 13B</td>
</tr>
<tr>
<td>Portal bifurcation</td>
<td>Right atrium</td>
<td>1</td>
<td>1</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>Inferior vena cava</td>
<td>7</td>
<td>4/5</td>
<td>102, 106, 111, 117, 131, 137</td>
</tr>
<tr>
<td></td>
<td>Median hepatic vein</td>
<td>1</td>
<td>1</td>
<td>40</td>
</tr>
<tr>
<td>Portal trunk side-to-side</td>
<td>Right atrium</td>
<td>1</td>
<td>1</td>
<td>112</td>
</tr>
<tr>
<td></td>
<td>Inferior vena cava</td>
<td>28</td>
<td>28</td>
<td>17, 23, 28, 35, 42, 45, 75, 60, 66, 88, 110, 113, 118, 132, 135, 140B</td>
</tr>
<tr>
<td></td>
<td>Left renal vein</td>
<td>2</td>
<td>2</td>
<td>133B</td>
</tr>
<tr>
<td>Portal vein end-to-side</td>
<td>Right atrium</td>
<td>1</td>
<td>0/1</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Azygous vein</td>
<td>1</td>
<td>0/1</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Inferior vena cava</td>
<td>24</td>
<td>9/20</td>
<td>6, 13, 34, 45, 75, 90, 92, 99, 102, 103, 112, 116, 118, 123, 131, 138B</td>
</tr>
<tr>
<td></td>
<td>Left renal vein</td>
<td>2</td>
<td>0/1</td>
<td>58, 122</td>
</tr>
<tr>
<td></td>
<td>Hepatic vein(s)</td>
<td>3</td>
<td>2/3</td>
<td>48, 131, 134</td>
</tr>
<tr>
<td>Gastric vein</td>
<td>Inferior vena cava</td>
<td>1</td>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Left renal vein</td>
<td>3</td>
<td>3</td>
<td>101</td>
</tr>
<tr>
<td>Inferior mesenteric vein</td>
<td>Iliac vein</td>
<td>2</td>
<td>2</td>
<td>97, 132</td>
</tr>
<tr>
<td>Superior mesenteric vein ± splenic vein</td>
<td>Azygous vein</td>
<td>4</td>
<td>1/4</td>
<td>19, 82, 133</td>
</tr>
<tr>
<td></td>
<td>Iliac vein</td>
<td>3</td>
<td>0/2</td>
<td>43, 91, 117</td>
</tr>
<tr>
<td></td>
<td>Left or right renal vein</td>
<td>8</td>
<td>1/7</td>
<td>3, 18, 61, 66, 93, 111</td>
</tr>
<tr>
<td></td>
<td>Left hepatic vein</td>
<td>1</td>
<td>0/1</td>
<td>85</td>
</tr>
<tr>
<td>Splenic vein</td>
<td>Right iliac vein</td>
<td>1</td>
<td>1</td>
<td>8B</td>
</tr>
<tr>
<td></td>
<td>Inferior vena cava</td>
<td>1</td>
<td>0/1</td>
<td>109</td>
</tr>
<tr>
<td></td>
<td>Renal vein</td>
<td>16</td>
<td>9/12</td>
<td>63, 71, 81, 101, 113, 126, 127, 130, 139B</td>
</tr>
</tbody>
</table>

Note: Polysplenia syndrome was present in children reported in references 9, 19, 21, 28, 61, 70, 81, 82, 103, 111, 127, 130, 133, 135, 136, 139, 140B

*Number of children for each anatomic type in whom the presence of an intrahepatic portal system was reported in the articles.
B, unpublished observations from Bicêtre Hospital; IVC, inferior vena cava.
with CPSS because galactose from milk bypasses the liver. The overall prevalence is close to 1:30,000 births and the prevalence of permanent CPSS can be estimated at 1:50,000. Possible clues to the understanding of the development of congenital portosystemic shunts include the following: (1) A genetic origin—of the 265 children who form the basis of this review, 11 had Down syndrome and 13 had another genetically defined disease or syndrome; all the anatomic types of shunts were found in these children. In addition a persistent ductus venosus was found in siblings in three pairs of twins. (2) A complex congenital malformative process—various anomalies of the kidneys, bile ducts (including biliary atresia), digestive system, bones, and brain have been recorded, but a congenital heart disease is the most frequent, as it was combined with a CPSS in 45 of the 265 studied, in most cases with shunts originating or ending outside the liver. (3) A polysplenia syndrome with azygos continuation of the inferior vena cava was present in 23 children, all with CPSS originating and ending outside the liver; indeed a recent study of children with the polysplenia syndrome reports the presence of a CPSS in at least 8% of cases. (4) The absence of ductus venosus during fetal life—occlusion or agenesis of the ductus venosus may be associated with the presence of abnormal vessels that allow the oxygenated blood from the umbilical vein to reach the fetal heart. Some of these vessels may persist, present as CPSS or may be combined with extreme hypoplasia of the portal venous system. In a few such children, the development of the CPSS was followed from the fetal to the postnatal stage. Absence of ductus venosus was in fact recorded in a few children reported for CPSS. A hemangioma of the liver—intrhepatic communications between branches of the portal vein and hepatic veins may be present in liver hemangiomas in early infancy; a few of them may persist while the hemangiomas regress and may present as intrahepatic shunts later in life.

Clinical Presentation and Investigation

Of the 265 children included in this review, their gender was reported in 255 cases; there were 113 girls and 142 boys. There was a female predominance in children with extrahepatic shunts, reported as type 1 Abernethy malformation (sex ratio: 0.57), and a male predominance in children with persistent ductus venosus (sex ratio: 2.6). Presenting symptoms are indicated in Table 2.

At the time of diagnosis, besides the possible signs of associated conditions or complications, the liver was not reported to be enlarged; a large number of cutaneous angiomas were reported in 10 children. Splenomegaly was recorded in five children with no patent signs of portal hypertension, excluding the children with biliary atresia. Serum alanineaminotransferase activity was above normal in 48 of 115 children tested (median value: 1.5×N; range 1.1–11×N), serum γ-glutamyltransferase activity was above normal in 25 of 50 children reported (median value: 3×N; range 1.5–15×N), prolonged prothrombin time was reported in 31 of 77 children tested, and the serum albumin concentration was below 35 g/L in 14 of the 35 tested. High ammonemia was reported in 123 of 156 children (median: 2×N; range 1.1–10×N), and high total serum bile acid concentration in 76 of 78 children. Note that one of the two normal bile acids values was recorded in a child with polysplenia syndrome before the Fontan operation, whose blood was flowing through the shunt from the systemic to the portal vein.

Doppler ultrasonography (US) is the key imaging modality for the diagnosis, monitoring during the therapeutic procedure, and follow-up of CPSS (Figs. 2, 3). In all types of CPSS, the portal and/or hepatic veins anatomy is modified and is the first obvious finding. Shunts joining a portal branch to a hepatic vein or the ductus venosus are easily diagnosed from the enlargement and in some cases tortuosity of both communicating vessels. The hypoplasia of the other portal

<table>
<thead>
<tr>
<th>Period of Time</th>
<th>Type of Finding</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prenatal (20–37 weeks)</td>
<td>Abnormal ultrasound</td>
<td>27</td>
</tr>
<tr>
<td>Neonatal</td>
<td>Total</td>
<td>78</td>
</tr>
<tr>
<td></td>
<td>Abnormal galactosemia test</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Congenital heart disease</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Neonatal cholestasis</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Fortuitous</td>
<td>1</td>
</tr>
<tr>
<td>After age 1 month</td>
<td>Total</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td>Complication of shunt*</td>
<td>117</td>
</tr>
<tr>
<td></td>
<td>Fortuitous imaging finding</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Abnormal liver test</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Not reported</td>
<td>2</td>
</tr>
</tbody>
</table>

*Including neonatal cholestasis, liver tumors, hepatopulmonary syndrome, pulmonary hypertension, encephalopathy, and others, see Outcome section.
branches or their reversed flow is indicative of the size of the shunt. Compensatory dilatation of the hepatic artery may be misleading by indicating a more complex arteriovenous malformation, but the continuous venous flow in the communicating veins helps to reach the correct diagnosis. Shunts joining the main portal vein to the inferior vena cava, end-to-side or side-to-side, may be more difficult to assess, as in most of the cases there is decreased liver size, sometimes with dysmophy. The main finding is the nonvisibility of the intrahepatic portal branches that often appear as hyperechoic bands surrounded by hypoechoic stripes, thus giving the portal space a layered appearance (Fig. 3). Portal flow may be slow or even absent, and arterial signal is the predominant recorded flow in the portal space. Side-to-side shunts usually present with ectasia of the portal vein at the level of the shunt. Liver tumors may sometimes mask the causal CPSS. Shunts joining afferent branches of the portal vein (i.e., the splenic or mesenteric veins) to the infrahepatic inferior vena cava or its affluent (the renal or iliac vein) may also be difficult to detect by Doppler US, as they are far from the liver, and only the effect of the diversion of the portal flow to the portal vein and its branches and the hyperarterialization of the liver may be observed.

Multidetector computed tomography (CT) with contrast injection is the next imaging modality to perform, to further document the anatomy and location of the shunt (Figs. 2,3). Together with maximum intensity projection and multiplanar reconstruction, it provides all the necessary information about the course of the shunt, its size, and orientation; it helps to define the best therapeutic option and access route for radiologists or surgeons. It is also useful for the detection of complicating liver tumors.

Magnetic resonance imaging (MRI) of the abdomen can also visualize the shunt, but is often less informative in small children than multidetector CT because of motion artifacts. However, its main indication is the evaluation of associated liver tumors, which present with variable signal intensity on T1- and T2-weighted images and variable contrast enhancement. Characterization of these lesions is difficult and biopsy is needed for diagnosis.

Angiography is performed either as an attempt to close the shunt percutaneously, or to detect the nonvisible portal vein and its intrahepatic branches and thus to provide arguments for closure in one step or more progressively in two steps. When portal branches are not visible on the initial opacification of the shunt, the occlusion test with a balloon occlusion catheter placed in the shunt, or in the inferior vena cava at the level of the shunt, is essential (Fig. 3). It helps to calibrate the venous communication, which is always more distensible than is thought, and shows the presence and location of the portal vein and the degree of hypoplasia of the intrahepatic portal branches. Portal pressure measurement is recorded before and after occlusion to evaluate the tolerance of the closure of the shunt.

The results of tests of radiologic or surgical occlusion of the shunt were reported in the literature in 70 children, including measurement of portal pressure in 59 and angiography in 30. Occlusion portal pressures were below 20 mm Hg in 23
children, between 20 and 29 in 20 children and 30 mm Hg or more (range 30–45) in 16. The increase in pressure was reported to be transient in three children, returning to values below 20 mm Hg within a few minutes to an hour of occlusion. An intrahepatic portal system, often very hypoplastic, was seen on angiograms in 26 out of 30 children, including 10 out of 12, whose occlusion portal pressure was between 30 and 45 mm Hg.

Per-rectal scintigraphy allows quantification of the shunt. The shunt ratios reported in the literature in 39 children range from 29 to 99% (median: 55%); the shunt ratio is significantly related to the level of ammonemia \((p = 0.0009; \text{Student's} \ t \text{test})\) and to the presence of clinical signs of encephalopathy \((p = 0.0062; \text{Fisher's exact test})\).

Brain MRI may reveal high signals of the globus pallidus bilaterally (Fig. 3) and also of the antehypophysis on T1-weighted images and proton MR spectroscopy abnormalities have also been reported. High signals of the globus pallidus, initially described in adult patients with cirrhosis and portal systemic encephalopathy, were later related to the degree of portal systemic shunting rather than the degree of liver failure, and are thought to reflect the presence of manganese deposits in the basal ganglia. The results of brain MRI were reported in 42 children with various anatomic types of CPSS: High signals of the globus pallidus were found in 35 children aged 18 months to 18 years, could be seen in children with no clinical signs of encephalopathy, and were associated with high blood manganese concentrations.

Outcome

Some small intrahepatic portosystemic shunts located between the portal branches and hepatic veins disappear spontaneously by age 1 to 2 years, but others, mostly the large shunts as well as the communications involving the extrahepatic portal veins and ductus venosus, persist throughout life and carry risks of complications. In the

**Figure 3.** A 12-year-old girl presenting with encephalopathy and congenital portosystemic shunt. (A) Liver ultrasonography (US) shows the lack of visibility of the intrahepatic portal branches with a layered appearance of portal spaces consisting of hyperechoic bands surrounded by hypoechoic stripes (white arrow). Note that the lumen of the left portal branch is not seen (star). (B) Computed tomography with contrast injection and sagittal reconstruction shows direct end-to-side communication between the confluence of the superior mesenteric vein (SMV) and the splenic vein on one side and the inferior vena cava (IVC) on the other. The dotted circle shows the position of the balloon in the IVC during occlusion test. (C) Occlusion test with injection in the SMV reveals the unexpected presence of an ectopic main portal vein (MPV) arising from a pancreatic vein (PV) with hypoplastic intrahepatic portal branches. (D) Brain magnetic resonance imaging (MRI) performed before closure of the shunt shows on T1-weighted images a high signal intensity in the pallidi (arrows). Surgical closure of the shunt was performed in one step. (E) Three months later, US showed the patency of the left portal branch (star) and its branches (arrow). (F) One year later, brain MRI showed the disappearance of the abnormal high signal intensity in the pallidi (arrows). Dramatic clinical improvement of the girl’s behavior occurred early after closure.
Neonatal Cholestasis

Twenty-four infants reported to have a neonatal cholestasis of an unknown cause also presented with a CPSS; they included all the anatomic types. In 10 cases, the shunt was found during the investigation of jaundice; in the other 14, it was identified by a galactosemia screening test, a prenatal ultrasonographic examination, or the investigation of a congenital heart disease. Intrauterine growth retardation was present in nine of 18 children whose birth weight and term were reported; premature birth was recorded in five of 19 children. Significant signs were thrombocytopenia in five children, prolonged prothrombin time despite parenteral vitamin K administration in eight children and lasting hypoglycemia in five of the eight in whom glycemia was reported. Stool discoloration was absent or transient in all six children in whom it was reported. Spontaneous resolution of jaundice occurred in 16 survivors. One may postulate that the presence of a shunt reduces the perfusion of the neonatal liver, a factor known to enhance the risk of cholestasis in neonates. The search for a shunt should be part of the investigation of a child with neonatal cholestasis, but its presence should not preclude the search for other causes of neonatal cholestasis, including biliary atresia, which is sometimes combined with a shunt, mostly with polysplenia, and respiratory chain disorders or adrenal insufficiency, which may present with hypoglycemia. In view of the good prognosis for this type of anoxoischemic cholestasis, early closure of the shunt is not necessary, but closure should be considered later if the shunt does not regress spontaneously.

Liver Tumors

Liver tumors have been reported in 64 children at a median age of 8 years (range 3 months–18 years). Although an unknown proportion of CPSS may remain clinically silent for decades, many complications can occur in childhood.

Neonatal Cholestasis

Figure 4 Two hundred forty-five complications reported in 182 children with a congenital portosystemic shunt. Fifty-one children presented with two simultaneous complications and six children with three complications. Including heart failure, membranoproliferative glomerulopathy, hypoglycemia, hyperandrogenism, acute or chronic pancreatitis, rectal bleeding, autoimmune disorders, protein-losing gastropathy, vaginal bleeding, fulminant liver failure, severe bleeding during surgery for scoliosis. Hatched bars: Malignant liver tumors.

Liver Tumors

Liver tumors have been reported in 64 children at a median age of 8 years (range 3 months–18 years). Although an unknown proportion of CPSS may remain clinically silent for decades, many complications can occur in childhood.

Liver Tumors

Liver tumors have been reported in 64 children at a median age of 8 years (range 3 months–18 years). Although an unknown proportion of CPSS may remain clinically silent for decades, many complications can occur in childhood.

Liver Tumors

Liver tumors have been reported in 64 children at a median age of 8 years (range 3 months–18 years). Although an unknown proportion of CPSS may remain clinically silent for decades, many complications can occur in childhood.

Liver Tumors

Liver tumors have been reported in 64 children at a median age of 8 years (range 3 months–18 years). Although an unknown proportion of CPSS may remain clinically silent for decades, many complications can occur in childhood.
all anatomic types of CPSS and led to the diagnosis of CPSS in 29 instances. Hepatopulmonary syndrome was a complication in 10 (none with biliary atresia) of the 23 children with CPSS and polysplenia syndrome and in 22 of the 242 children without polysplenia syndrome (p < 0.0001; Fisher’s exact test). Children with CPSS and polysplenia presented with hypoxemia at a younger age (3 months–2 years; mean: 1 year) than children without polysplenia (1 year–11 years; mean: 5½ years; p < 0.0001, unpaired Student’s t test). Six of the children reported in the literature did not undergo any treatment; follow-up was available for three: One died of a brain abscess 6 months after diagnosis, one presented with pulmonary hypertension and is alive after a follow-up of 8 years, and one has stable hypoxemia after 1 year. Eight children underwent liver transplantation; follow-up is available for seven and shows full regression of hypoxemia 1 month to 1 year after transplantation. Nineteen children underwent surgical or radiologic closure of the CPSS in one or two steps: full regression of hypoxemia was observed in all but one child (range up to 10 years; mean: 2); in this child, pulmonary arteriography showed the persistence of pulmonary arteriovenous shunts that are considered to be associated arteriovenous malformations;118; in another child, the emergence of additional portosystemic shunts was complicated by pulmonary hypertension 4 years after the regression of hypoxemia.78,110 These results indicate that CPSS may be present in children with unexplained hypoxemia and pulmonary arteriovenous shunting and that closure of the CPSS cures hypoxemia in virtually all cases, but requires careful follow-up. In addition, one must mention two reports of hepaticopulmonary syndrome disclosing a previously unknown CPSS 8 months and 8 years, respectively, after liver transplantation for biliary atresia and the polysplenia syndrome.136,157 Search for a congenital portosystemic shunt is recommended in children with biliary atresia, polysplenia and hepatopulmonary syndrome and closure of the shunt might be considered in lieu of transplantation whenever possible.

### Pulmonary Hypertension

Pulmonary hypertension has been reported in 30 children at ages ranging from the neonatal period to 15 years (mean: 5 years 4 months) with all anatomic types of shunts.24,35,42,50,51,58,61,99,101,107,109,110,114,118,127,129,130,133,138 Signs of pulmonary hypertension were the occasion of the diagnosis of CPSS in 19 instances, and consisted of dyspnea, fainting, screening by clinical examination or echocardiography, or rapid right heart failure leading to death. The latter was observed in two children aged 12 and 20 months, who had extrahepatic shunts.58,130 There was a link between pulmonary hypertension and hepatopulmonary syndrome in five instances: in two children hepatopulmonary syndrome was followed by pulmonary hypertension after 3 to 4 years. In the other three children, the simultaneous presence of hepatopulmonary syndrome and pulmonary hypertension was reported, but the results of right heart catheterizations were not mentioned. Fifteen children fulfilled the criteria defined for portopulmonary hypertension158. In two, postmortem study showed lesions of plexogenic pulmonary arteriopathy,58,130 and in 13, the results of right heart catheterization showed elevated pulmonary resistances ranging from 5 to 38 wood units-m² (median: 7).51,101,118,133 – Table 3 indicates the outcome for these children: Six children died and pulmonary arterial pressures and resistances did not return to normal values after treatment in survivors. These ominous results indicate that CPSS must be searched for in children who present with unexplained pulmonary hypertension, and that conversely, scrupulous care is mandatory in children with CPSS to detect the emergence of pulmonary hypertension early, even in very young children, to provide the child with the best chances of regression after early closure before the development of irreversible pulmonary vascular lesions.

### Encephalopathy

Neurologic abnormalities were reported in 64 children with a CPSS, excluding patients with biliary atresia and portal systemic encephalopathy.4,5,11,13,16,17,24,27,31,34,35,39,41,43,45.

#### Table 3 Outcome of 15 Children with a Congenital Portosystemic Shunt Complicated by Pulmonary Hypertension Proven Either by Right Heart Catheterization Providing the Results of the Pulmonary Vascular Resistances (13 Children Aged 8 Months to 12 Years; MdN: 7 Years) or by Postmortem Examination Showing Pulmonary Plexiform Arteriopathy at Ages 12 and 20 Months, Respectively

<table>
<thead>
<tr>
<th>Number of Children</th>
<th>Pulmonary Vascular Resistances (Wood u-m²)</th>
<th>Treatment</th>
<th>Outcome (Follow-Up)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>5–38 (MdN: 7)*</td>
<td>None</td>
<td>Alive</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 (3 Years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stable PP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 (0–12 Years)</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>Drug(s)†</td>
<td>Improved PP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 (1–5 Years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stable PP</td>
</tr>
<tr>
<td>1</td>
<td>8</td>
<td>Liver transplantation</td>
<td>Dead</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 (3 Years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Improved PP</td>
</tr>
<tr>
<td>5</td>
<td>5–26 (MdN: 7)</td>
<td>Shunt closure ± drug(s)†</td>
<td>Alive</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 (2–13 years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PP: Stable (1 pt), improved (2 pts), impaired (2 pts)</td>
</tr>
</tbody>
</table>

*Results in five children who underwent right heart catheterization.
†Iloprost, Bosentan, and/or Sildenafil.
MdN, Median; PP, pulmonary artery pressure; pt, patient.
Because of the malformations, past medical histories and genetic syndromes sometimes associated with the CPSS, it is not always easy to attribute an abnormal neurologic sign to the possible consequence of portal systemic encephalopathy and/or to the brain toxicity of ammonia and manganese. The reported abnormalities can be divided into three main categories: (1) clear-cut signs of portal systemic encephalopathy, including intermittent episodes of lethargy or confusion after meals, or abnormal or bizarre behavior sometimes combined with irritability, agitation, or disorientation, slow waves on electroencephalograms (EEGs) and extrapyramidal signs on neurologic examination; (2) speech delay, mental retardation, sometimes combined with seizures; and (3) difficulties at school, behavioral problems and attention hyperactivity disorders in older children. The neurologic symptoms were observed at all ages, could be observed with all anatomic types of shunt and may be related to the magnitude of the shunt as measured by per-rectal scintigraphy (see above). Raised ammonemia was present in all but three children and high signal intensity in the globus pallidus on brain MRI was present in 15 of 18 children studied. Closure of the shunt or liver transplantation was performed in 46 children. Follow-up information was available for 28 children: Full regression of neurologic symptoms was observed in seven children, significant subjective improvement was noted by the parents in 18, including one child whose seizures disappeared, and no modification was noted in three children. Ammonemia levels were normal in all 24 children tested after closure of the shunt. High signal intensity in the globus pallidus disappeared in all six children studied 3 months to 3 years (mean: 1 year 5 months) after shunt closure. These data suggest that abnormal neurologic symptoms or behavior, as well as school difficulties, especially when combined with high ammonemia, abnormal brain MRI, and improvement after closure of the shunt, could be the consequence of portal systemic encephalopathy and can be used as an argument for closure of the shunt.

**Other Complications**

Other complications have been reported in a few children that might be consequences of the CPSS: They include heart failure, hypoxemia due to pulmonary arteriovenous shunting, pulmonary artery hypertension, encephalopathy with hyperammonemia, and glomerulopathy are known complications of cirrhosis, and their occurrence in children with congenital portosystemic shunts and minimal liver histologic lesions argues in support of the major role of communications between the portal blood and the systemic circulation in the origin of these conditions. The high incidence of liver tumors or nodules, whether benign or malignant, in children with congenital portosystemic shunts is reminiscent of what was described in some strains of rats and strengthens the concept of a portal deprivation syndrome in which abnormal portal venous flux results in the production of liver nodules of various kinds, as suggested to occur in patients with hepatopulmonary syndrome, focal nodular hyperplasia, and focal regenerative hyperplasia, as well as in patients with portal vein obstruction after a surgical portosystemic shunt.

In all, with a follow-up ranging from 0 to 20 years, 19 of the 265 children included in this review died, nine possibly of causes unrelated to the CPSS and 10 of causes very likely to be the consequence of the shunts, one each of brain abscess with hepatopulmonary syndrome, hepatocellular carcinoma or acute liver failure, and seven children with pulmonary hypertension.

**Management**

Whenever a CPSS is found in a child, either during the investigation of a complication, during the neonatal period, or later as a fortuitous finding, one has first to make sure that the shunt is not the consequence of portal hypertension, or during early infancy, of a liver hemangioma that would require a specific treatment. Once the congenital and isolated nature of the shunt has been ascertained, the recommended investigations are indicated on Table 4.

**Table 4** Schematic Proposed Initial Investigation for a Child Presenting with a Congenital Portosystemic Shunt

<table>
<thead>
<tr>
<th>Blood Tests:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum transaminases and y-glutamyl transferase activities</td>
<td></td>
</tr>
<tr>
<td>Coagulations studies</td>
<td></td>
</tr>
<tr>
<td>Pre- and postprandial ammonemia and glyceremia</td>
<td></td>
</tr>
<tr>
<td>Fasting serum total bile acids concentration</td>
<td></td>
</tr>
<tr>
<td>Blood manganese concentration</td>
<td></td>
</tr>
<tr>
<td>Serum α-fetoprotein concentration (in case of liver tumor)</td>
<td></td>
</tr>
<tr>
<td>Imaging Studies:</td>
<td></td>
</tr>
<tr>
<td>Abdominal Doppler color ultrasonography</td>
<td></td>
</tr>
<tr>
<td>Multidetector CT and/or MRI with contrast injection</td>
<td></td>
</tr>
<tr>
<td>Angiography of the shunts with or w/o occlusion test</td>
<td></td>
</tr>
<tr>
<td>Echocardiography</td>
<td></td>
</tr>
<tr>
<td>Brain MRI</td>
<td></td>
</tr>
<tr>
<td>Per-rectal scintigraphy</td>
<td></td>
</tr>
<tr>
<td>Others:</td>
<td></td>
</tr>
<tr>
<td>Psychometric evaluation</td>
<td></td>
</tr>
<tr>
<td>Percutaneous O₂ saturation</td>
<td></td>
</tr>
<tr>
<td>Proteinuria</td>
<td></td>
</tr>
<tr>
<td>Liver histology (when indicated)</td>
<td></td>
</tr>
<tr>
<td>Liver tumor histology (when indicated)</td>
<td></td>
</tr>
</tbody>
</table>

CT, Computed tomography; MRI, magnetic resonance imaging.
Because of the severity of its complications, closure of a congenital portosystemic shunt is necessary.

**Techniques for Closure**

As a general rule, percutaneous closure can be performed when an occlusive device can be fixed in position in the shunt, without compromising the development of the portal branches, the flow in the inferior vena cava and the normal hepatic veins and also the venous drainage of the other organs such as the spleen and kidneys. This therapeutic option applies to shunts between portal branches and hepatic veins that can be closed by means of Amplatzer devices or coils, depending on the size and number of communications. A patent ductus venosus can be successfully managed in this way, except when it is too wide or short to safely block the device in its lumen, in which case surgery must be undertaken. Shunts joining a splenic or mesenteric vein to an affluent of the inferior vena cava such as a renal vein or an iliac vein can also be easily closed percutaneously when they consist of end-to-side communications. On the other hand, when the shunt is side-to-side, surgery is certainly preferable, at least in young children, to the placement of a covered stent in the lumen of the efferent vessel, as the latter option would require lifelong anticoagulation treatment and would probably become inadequate in size with growth. For the same reasons, side-to-side shunts between the main portal vein and the inferior vena cava are also indications for surgery, usually performed in one step. On the contrary, end-to-side shunts between the main portal vein and the inferior vena cava usually require a two-step surgical procedure to avoid acute severe portal hypertension.

---

**Figure 5** A schematic proposal for the management in a child with congenital portosystemic shunt. (*with the exception of an early complication, other than cholestasis, that requires closure of the shunt; **no precise cut-off value of occlusion portal pressure can be given to decide upon closure in one or two stages, but by and large, a stable occlusion portal pressure above 32 mm Hg should lead to the consideration of a two-stage procedure, especially if no portal vein is visible on the occlusion angiogram. During surgery, the most important point is the tolerance of the small bowel during the occlusion (see text).
The first step, consisting of banding of the shunt, allows the intrahepatic portal branches to progressively develop through a cavernomatous hepatopetal network. Complete closure a few months later can then be performed without significant portal hypertension. In complex forms of shunt, successive radiologic and surgical procedures are required to tailor the best therapeutic option for the closure of single or multiple shunts and finally to avoid liver transplantation.

Surgical closure of the shunt is indicated in patients considered unsuitable for endoluminal closure. The rules of this surgery are as follows: (1) The shunt must be occluded as close as possible to the caval system to preserve the maximal number of intrahepatic portal branches; (2) the occlusion must be checked to see that it does not result in excessive portal pressure and/or in small bowel cyanosis and edema; and (3) the thrombosis of blind portal segments must be prevented. The site of occlusion should be chosen after a careful multidisciplinary work-up. The details of the surgical approach (open, or rarely, laparoscopic, mobilization of liver, etc.) are planned according to the route of the shunt. Intraoperative monitoring of portal blood pressure during a 15-minute clamping test is strongly recommended. In case of good bowel tolerance, closure of the shunt may be achieved as a one-stage procedure by ligation, placement of clips or caval partition. In case of poor tolerance, a two-stage procedure is necessary, i.e., banding of the shunt followed by delayed closure after enlargement of intrahepatic portal vessels, sometimes after development of a portal network.34,44,118 Heparin is given before clamping and continued for one to several weeks, depending on the promptness of intrahepatic portal enlargement and on the possible formation of blood clots in blind segments. Shunt disappearance and development of intrahepatic portal branches are assessed by repeat Doppler US sonography, and by CT or MRI angiogram when necessary.

After closure of the shunt, the abnormalities shown by liver tests and coagulation studies regress. Ammonemia returns to normal within a day and serum bile acids are again normal after a few days.71,107 Careful follow-up is necessary for several years to check for the regression of complications when present, for long-term management of persistent complications such as pulmonary hypertension, and to detect the possible emergence of an additional shunt that would require additional closure108,118, the latter is best detected by a combination of abdominal ultrasonography and assay for serum bile acids concentration.

Indications for Closure

With the exception of neonatal cholestasis, which resolves spontaneously, closure of the shunt is mandatory whenever a complication is present (Fig. 3).318 When no complication is detected, closure of the shunt can be postponed in cases of a small intrahepatic shunt (i.e., between a branch of the portal vein and a hepatic vein) found in early infancy because there is a reasonable hope of spontaneous shunt regression during the first year. In all other cases, closure of the shunt should be considered early, to prevent complications from occurring, for four reasons: (1) hepatopulmonary syndrome and pulmonary hypertension may be present during the very first years of life; (2) the regression of pulmonary hypertension cannot be ascertained once irreversible lesions of the pulmonary arteries are present; (3) chronic hyperammonemia and high blood levels of manganese have adverse effects on the developing brain160,161; and (4) the plasticity of the intrahepatic portal system may be better in younger children.121 The plasticity of the intrahepatic portal system will allow revascularization of the liver even when the intrahepatic portal system is not detectable on imaging studies and when portal pressure is high during an occlusion test. The experience gained over the past 15 years indicates that there is very little place left, if any, for liver transplantation in the management of congenital portosystemic shunts in children.

References


This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Peker A, Ucar T, Kuloglu Z, Ceyhan K, Tutar E, Fitoz S. Congenital Portosystemic Shunts in Children

118

117

116

115

114

113

112

111

110

109

108

107

106

105

104

103

102

101

100

99


Cho YK, Chang NK, Ma JS. Successful transcatheter closure of a large patent ductus venous with the Amplatz vascular plug II. Pediatr Cardiol 2009;30(4):540–542


Brassant O. Ammonia toxicity to the brain: effects on creatine metabolism and transport and protective roles of creatine. Mol Genet Metab 2010;100(Suppl 1):S52–S58